Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs

Nature Neuroscience

Volumn 11, Issue 8, 2008, Pages 932-939

  Bateup, Helen S ^a   Svenningsson, Per ^a,b   Kuroiwa, Mahomi ^c   Gong, Shiaoching ^a   Nishi, Akinori ^a,c   Heintz, Nathaniel ^a   Greengard, Paul ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CLOZAPINE; COCAINE; HALOPERIDOL; NEUROLEPTIC AGENT; PHOSPHOPROTEIN DARPP 32; PSYCHOSTIMULANT AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SPECIFICITY; CELL TYPE; DRUG TARGETING; ENZYME REGULATION; FLUORESCENCE IN SITU HYBRIDIZATION; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIPSYCHOTIC AGENTS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CLOZAPINE; COCAINE; CORPUS STRIATUM; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; GLOBUS PALLIDUS; HALOPERIDOL; MICE; MICE, TRANSGENIC; NEURONS; ORGAN CULTURE TECHNIQUES; PHOSPHORYLATION; SUBSTANTIA NIGRA;

EID: 48149108931     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/nn.2153     Document Type: Article

References (38)

1. Greengard, P. The neurobiology of slow synaptic transmission. Science 294, 1024-1030 (2001).
2. Greengard, P., Allen, P.B. & Nairn, A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23, 435-447 (1999).
3. Nishi, A. et al. Amplification of dopaminergic signaling by a positive feedback loop. Proc. Natl. Acad. Sci. USA 97, 12840-12845 (2000).
4. Ahn, J.H. et al. Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56δ subunit. Proc. Natl. Acad. Sci. USA 104, 2979-2984 (2007).
5. Bibb, J.A. et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signaling in neurons. Nature 402, 669-671 (1999).
6. Svenningsson, P. et al. DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 44, 269-296 (2004).
7. Zachariou, V. et al. Phosphorylation of DARPP-32 at threonine 34 is required for cocaine action. Neuropsychopharmacology 31, 555-562 (2006).
8. Zhang, Y. et al. Cocaine self-administration in mice is inversely related to phosphorylation at Thr34 (protein kinase A site) and Ser130 (kinase CK1 site) of DARPP-32. J. Neurosci. 26, 2645-2651 (2006).
9. Hakansson, K. et al. Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors. J. Neurochem. 96, 482-488 (2006).
10. Gerfen, C.R. et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432 (1990).
11. Missale, C., Nash, S.R., Robinson, S.W., Jaber, M. & Caron, M.G. Dopamine receptors: from structure to function. Physiol. Rev. 78, 189-225 (1998).
12. Stoof, J.C. & Kebabian, J.W. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294, 366-368 (1981).
13. Albin, R.L., Young, A.B. & Penney, J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-375 (1989).
14. Fink, J.S. et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res. Mol. Brain Res. 14, 186-195 (1992).
15. Nishi, A., Snyder, G.L. & Greengard, P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 17, 8147-8155 (1997).
16. Pothos, E.N., Przedborski, S., Davila, V., Schmitz, Y. & Sulzer, D. D2-like dopamine autoreceptor activation reduces quantal size in PC12 cells. J. Neurosci. 18, 5575-5585 (1998).
17. Schmitz, Y., Schmauss, C. & Sulzer, D. Altered dopamine release and uptake kinetics in mice lacking D2 receptors. J. Neurosci. 22, 8002-8009 (2002).
18. Miyamoto, S., Duncan, G.E., Marx, C.E. & Lieberman, J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79-104 (2005).
19. Fredholm, B.B., Battig, K., Holmen, J., Nehlig, A. & Zvartau, E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51, 83-133 (1999).
20. Svenningsson, P., Le Moine, C., Fisone, G. & Fredholm, B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 59, 355-396 (1999).
21. Lindskog, M. et al. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature 418, 774-778 (2002).
22. Nestler, E.J. Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci. 2, 119-128 (2001).
23. Yan, Z. et al. Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. Nat. Neurosci. 2, 13-17 (1999).
24. Pozzi, L. et al. Opposite regulation by typical and atypical antipsychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. J. Neurochem. 86, 451-459 (2003).
25. Svenningsson, P. et al. Activation of adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience 84, 223-228 (1998).
26. Farde, L. et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 49, 538-544 (1992).
27. Jin, L.Q., Wang, H.Y. & Friedman, E. Stimulated D(1) dopamine receptors couple to multiple Galpha proteins in different brain regions. J. Neurochem. 78, 981-990 (2001).
28. Voorn, P., Vanderschuren, L.J., Groenewegen, H.J., Robbins, T.W. & Pennartz, C.M. Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci. 27, 468-474 (2004).
29. Nishi, A. et al. Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc. Natl. Acad. Sci. USA 102, 1199-1204 (2005).
30. Cameron, D.L. & Williams, J.T. Dopamine D1 receptors facilitate transmitter release. Nature 366, 344-347 (1993).
31. Le Moine, C., Svenningsson, P., Fredholm, B.B. & Bloch, B. Dopamine-adenosine interactions in the striatum and the globus pallidus: inhibition of striatopallidal neurons through either D2 or A2A receptors enhances D1 receptor-mediated effects on c-fos expression. J. Neurosci. 17, 8038-8048 (1997).
32. Day, M. et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat. Neurosci. 9, 251-259 (2006).
33. Lee, K.W. et al. Cocaine-induced dendritic spine formation in D1 and D2 dopamine receptor-containing medium spiny neurons in nucleus accumbens. Proc. Natl. Acad. Sci. USA 103, 3399-3404 (2006).
34. Ade, K.K., Janssen, M.J., Ortinski, P.I. & Vicini, S. Differential tonic GABA conductances in striatal medium spiny neurons. J. Neurosci. 28, 1185-1197 (2008).
35. Gong, S., Yang, X.W., Li, C. & Heintz, N. Highly efficient modification of bacterial artificial chromosomes (BACs) using novel shuttle vectors containing the R6Kgamma origin of replication. Genome Res. 12, 1992-1998 (2002).
36. Svenningsson, P. et al. Cellular distribution of adenosine A2A receptor mRNA in the primate striatum. J. Comp. Neurol. 399, 229-240 (1998).
37. Valjent, E. et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl. Acad. Sci. USA 102, 491-496 (2005).
38. Hemmings, H.C. Jr. & Greengard, P. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein: regional, tissue and phylogenetic distribution. J. Neurosci. 6, 1469-1481 (1986).